Results 71 to 80 of about 697 (97)

Mid-regional pro-adrenomedullin (MR-proADM), a marker of positive fluid balance in critically ill patients: results of the ENVOL study. [PDF]

open access: yesCrit Care, 2016
Vigué B   +10 more
europepmc   +1 more source

Micronutrient Status and Breast Cancer: A Narrative Review. [PDF]

open access: yesInt J Mol Sci
Forma A   +7 more
europepmc   +1 more source

Renal Production, Uptake, and Handling of Circulating αKlotho. [PDF]

open access: yesJ Am Soc Nephrol, 2016
Hu MC   +11 more
europepmc   +1 more source

Small-Molecule Trk Agonists: Where Do We Go from Here? [PDF]

open access: yesJ Med Chem
Thompson TS, Sefiani A, Burgess K.
europepmc   +1 more source

Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers. [PDF]

open access: yesInt J Mol Sci
Chatzipieris FP   +3 more
europepmc   +1 more source

In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep.

Journal of Pharmacology and Experimental Therapeutics, 1996
Knowledge regarding the in vivo metabolic fate of the glycoprotein erythropoietin (EPO) is incomplete. To determine whether EPO pharmacokinetics are perturbed by ablation of the kidneys or liver or by anesthesia, EPO pharmacokinetic parameters were determined in adult sheep.
J A, Widness   +5 more
exaly   +3 more sources

Tunicamycin modulates binding of 125I-erythropoietin to Friend erythroleukemia cells.

Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society, 1989
The effects of tunicamycin and neuraminidase treatment on the specific binding of 125I-erythropoietin to a murine erythroleukemia cell clone, B8, were investigated. Neuraminidase treatment of B8 cells did not affect the specific binding of erythropoietin, but tunicamycin treatment caused a 2.5 to 4-fold increase in the amount of 125I-erythropoietin ...
H, Fukamachi   +5 more
openaire   +1 more source

Home - About - Disclaimer - Privacy